Literature DB >> 28888053

Mesenchymal Stem Cells Overexpressing Interleukin-35 Propagate Immunosuppressive Effects in Mice.

H Guo1,2, N Zhao2, H Gao1,2, X He1,2.   

Abstract

To explore generation of interleukin (IL)-35-expressing mouse adipocyte-derived mesenchymal stem cells (Ad-MSCs) using lentiviral vector and their potential immunosuppressive effects in mice. Ad-MSCs were isolated and cultured in vitro and transfected with a lentivirus vector for overexpression of the therapeutic murine IL-35 gene. IL-35 expression in transfected MSCs (IL-35-MSCs) was quantified by enzyme-linked immunosorbent assay (ELISA). The lymphocytes subsets after one-way mixed lymphocyte culture and in vivo intravenous transplantation were analysed by flow cytometry to evaluate the immunosuppressive effects of IL-35-MSCs. ELISA was performed to examine IL-10, IL-17A and IL-35 expression in lymphocyte culture. Mouse Ad-MSCs were isolated and cultured. IL-35 was expressed in the MSC supernatant and serum after IL-35 transduction into Ad-MSCs by lentiviral vector transfection in vitro and in vivo. The percentage of CD4+ CD25+ T regulatory (Treg) cells in mice treated with IL-35-MSCs significantly increased. IL-35-MSCs upregulated the CD4+ CD25+ Treg cells in the allogeneic mixed lymphocyte reaction system, and lowered the percentage of CD4+ T cells compared with the other two control groups (P < 0.01). IL-17A expression significantly decreased and IL-10 expression significantly increased in IL-35-MSCs and MSCs when compared by ELISA to the control groups (P < 0.01). IL-35-transduced Ad-MSCs in vivo can enhance proliferation of CD4+ CD25+ Treg cells and suppress the function of effector T cells such as T helper (Th) 1, Th2 and Th17 cells and may reduce the development of allograft rejection. Our data suggest that transduced Ad-MSCs overexpressing IL-35 may provide a useful approach for basic research on cell-based immunotolerance therapy for inducing transplantation tolerance.
© 2017 The Foundation for the Scandinavian Journal of Immunology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28888053     DOI: 10.1111/sji.12613

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

Review 1.  Modulation of cell signaling pathways by Phyllanthus amarus and its major constituents: potential role in the prevention and treatment of inflammation and cancer.

Authors:  Hemavathy Harikrishnan; Ibrahim Jantan; Akilandeshwari Alagan; Md Areeful Haque
Journal:  Inflammopharmacology       Date:  2019-12-02       Impact factor: 4.473

2.  Toll-Like Receptor 3 Activator Preconditioning Enhances Modulatory Function of Adipose‑Derived Mesenchymal Stem Cells in a Fully MHC-Mismatched Murine Model of Heterotopic Heart Transplantation.

Authors:  Zhiye Bao; Jingjing Li; Pengju Zhang; Qi Pan; Boqian Liu; Jiayi Zhu; Qian Jian; Degong Jia; Caiyu Yi; Christian J Moeller; Hao Liu
Journal:  Ann Transplant       Date:  2020-05-05       Impact factor: 1.530

Review 3.  A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.

Authors:  Kripa Guram; Sangwoo S Kim; Victoria Wu; P Dominick Sanders; Sandip Patel; Stephen P Schoenberger; Ezra E W Cohen; Si-Yi Chen; Andrew B Sharabi
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 8.786

Review 4.  Interleukin-35 in autoimmune dermatoses: Current concepts.

Authors:  Yuming Xie; Huilin Zhang; Junke Huang; Qing Zhang
Journal:  Open Med (Wars)       Date:  2022-03-21

5.  Interleukin 35 induced Th2 and Tregs bias under normal conditions in mice.

Authors:  Xiaoning Zhang; Zhiqiang Zhang; Zhiqiang He; Mingyan Ju; Jiaci Li; Jinghua Yuan; Yaqing Jing; Keqiu Li; Yi Liu; Guang Li
Journal:  PeerJ       Date:  2018-09-21       Impact factor: 2.984

Review 6.  Mesenchymal stem cells overexpressing IL-35: a novel immunosuppressive strategy and therapeutic target for inducing transplant tolerance.

Authors:  Hao Guo; Baozhu Li; Wei Wang; Na Zhao; Haopeng Gao
Journal:  Stem Cell Res Ther       Date:  2018-09-26       Impact factor: 6.832

7.  Pretreatment with interleukin 35-engineered mesenchymal stem cells protected against lipopolysaccharide-induced acute lung injury via pulmonary inflammation suppression.

Authors:  Xiaoning Zhang; Zhiqiang Zhang; Mingyan Ju; Jiaci Li; Yaqing Jing; Yuxia Zhao; Chao Gu; Ming Dong; Guang Li; Yi Liu
Journal:  Inflammopharmacology       Date:  2020-03-13       Impact factor: 4.473

Review 8.  Regulatory Role of Mesenchymal Stem Cells on Secondary Inflammation in Spinal Cord Injury.

Authors:  Qi-Ming Pang; Si-Yu Chen; Sheng-Ping Fu; Hui Zhou; Qian Zhang; Jun Ao; Xiao-Ping Luo; Tao Zhang
Journal:  J Inflamm Res       Date:  2022-01-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.